Navigation Links
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
Date:9/30/2009

p>

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential for OPAXIO to be proved safe and effective (or to achieve response rates) for the treatment of the indications noted in this press release or any other indication, determinations by regulatory, patent and administrative governmental authorities, the potential that OPAXIO will not produce high rates of complete remission in patients with advanced esophageal cancer, the possibility that the registration trial for OPAXIO as a radiation sensitizer will not occur, the possibility that the U.S. Food and Drug Administration will not approve a phase III registration strategy for paclitaxel poliglumex if proposed by CTI, the potential that Novartis will not exercise its option, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and selling OPAXIO. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    www.CellT
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
3. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
6. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
7. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
10. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... WARSAW, Ind. , Nov. 18, 2014  Zimmer ... that it has agreed with the European Commission (the ... of Zimmer,s proposed acquisition of Biomet by a limited ... with certain additional information. Deadline extensions ... been working closely with the regulatory authorities to facilitate ...
(Date:11/18/2014)... 2014  Cardica, Inc. (Nasdaq: CRDC ... approved management,s recommendation to shift Cardica,s primary focus ... XCHANGE® 30 surgical stapler to improving its performance ... result, Cardica has temporarily suspended the controlled commercial ... of the MicroCutter XCHANGE 30 surgical stapler from ...
(Date:11/18/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Monday, December 8, 2014 at 9:00 a.m. Eastern Time to ... th American Society of Hematology Annual Meeting and Exposition.  ... by dialing 877-443-5662 or access the webcast at www.isispharm.com ... time at the same address. ABOUT ISIS ...
Breaking Medicine Technology:Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 2Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 3Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 4Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 5Cardica Announces Shift In Focus 2Cardica Announces Shift In Focus 3Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 3
... May 26, 2011 Kensey Nash Corporation (Nasdaq: ... Global Healthcare Conference at The Grand Hyatt in New York, ... Kaufmann, Kensey Nash,s President and CEO, will deliver the Company,s ... live webcast of the Kensey Nash presentation, go to ...
... Pa., May 26, 2011 ViroPharma Incorporated (NASDAQ: ... Swell , a twenty-five minute film that allows families dealing ... share the challenges and triumphs of living with a chronic ... HAE, often times through many generations of the same family. ...
Cached Medicine Technology:ViroPharma Launches 'Swell,' an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema 2ViroPharma Launches 'Swell,' an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema 3
(Date:11/18/2014)... 18, 2014 A+ Secure Packaging, ... nutraceutical, dietary supplements and more, announced today that ... Good Manufacturing Practices (GMP) Registration for dietary supplements ... from NSF International verifies the A+ Secure Packaging ... compliance requirements of its clients by demonstrating the ...
(Date:11/18/2014)... 2014 Recently, Wigsbuy has introduced its ... are offered at greatly discounted prices now, up to 85% ... of human hair products, offering many real and synthetic hair ... global customers, Wigsbuy uses high quality materials to make its ... with the trend. , “We are offering a full ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. 17, ... not have significant heart-health benefits for older people, new ... than 14,000 Japanese people aged 60 to 85, found ... attacks and strokes between people who took aspirin and ... prevention with daily low-dose aspirin does not reduce the ...
(Date:11/18/2014)... By Dennis Thompson HealthDay ... doctor from Sierra Leone who became infected with Ebola in his ... Dr. Martin Salia had arrived Saturday at Nebraska Medical Center ... at a hospital in Sierra Leone,s capital city of Freetown. ... that have been ravaged by the Ebola outbreak that began last ...
(Date:11/17/2014)... 17, 2014 A Diet Doc ... throughout the country are turning back the clock on ... This is because the company has recently added their ... impressive collection of prescription and non-prescription diet products and ... Diet Doc’s best anti-aging human growth hormone ...
Breaking Medicine News(10 mins):Health News:A+ Secure Packaging, LLC Earns NSF International Good Manufacturing Practices (GMP) Registration for Dietary Supplements and Certification for Sport 2Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Doctor With Ebola Dies at Nebraska Hospital 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3
... Lower pay, fewer marriages among those who had depression, ... 17 (HealthDay News) -- Children who experience psychological disorders ... headed for a financially depressed adulthood, new research suggests. ... are less likely to get married or maximize their ...
... ... Village at ProprietorsGreen, a luxury senior rental community developed by Norwell-based ... has opened in Marshfield, Massachusetts. Despite an economic climate that ... on schedule, and opened with 40 percent of its independent living ...
... ... provider of solutions for the workers, compensation and liability markets, announced that it has ... drug requirements pertaining to Medicare Set-Asides (MSA). , ... Tampa, Florida (Vocus) May 17, 2010 -- PMSI ...
... diseases in middle age, despite an absence of family history ... blame, according to a new study conducted by researchers at ... the National Institutes of Health. The study also ... help identify those genetic abnormalities and allow detection before the ...
... the Queensland Institute of Medical Research (QIMR) and the Royal ... successfully treated it by performing an experimental stem cell transplant. ... out of hospital Katie Pulling had almost given up hope. ... the doctors say, ,We don,t know what is wrong, ,We ...
... ... for. Flexible Assembly Systems uncovers the great torque screwdriver mystery with its very own Torque ... (PRWEB) ... know what to look for. A torque screwdriver comes in many different variations, including ...
Cached Medicine News:Health News:Kids' Psychological Problems Have Long-Term Effects 2Health News:Village at Proprietors Green Opens on South Shore, Introducing Innovative Senior Living to Boston Area 2Health News:PMSI Advocacy Efforts Prompt CMS to Improve MSA Review Methodology 2Health News:PMSI Advocacy Efforts Prompt CMS to Improve MSA Review Methodology 3Health News:Lung disease may be genetic, despite lack of family history 2Health News:Australian researchers identify a new disease 2Health News:Flexible Assembly Systems Announces Torque Screwdriver Application Guide 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: